{"id":"NCT01839188","sponsor":"MCM Vaccines B.V.","briefTitle":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","officialTitle":"A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-01","primaryCompletion":"2014-03-19","completion":"2014-03-19","firstPosted":"2013-04-24","resultsPosted":"2019-02-25","lastUpdate":"2019-02-25"},"enrollment":385,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Neisseria Meningitidis","Bacterial Infections","Virus Diseases"],"interventions":[{"type":"BIOLOGICAL","name":"PR5I","otherNames":["V419","Vaxelis®","DTaP-HB-IPV-Hib"]},{"type":"BIOLOGICAL","name":"Pediacel®","otherNames":["DTaP-IPV-Hib"]},{"type":"BIOLOGICAL","name":"NeisVac-C®","otherNames":[]},{"type":"BIOLOGICAL","name":"RotaTeq®","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar 13®","otherNames":["PCV-13"]}],"arms":[{"label":"PR5I (V1); Pediacel® (V2); PR5I (V3)","type":"EXPERIMENTAL"}],"summary":"To evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel at 4 months of age\n\nPrimary objectives\n\n* To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B (HB) one month after completion of the mixed schedule\n* To demonstrate that the mixed schedule induces acceptable responses for Haemophilus influenzae type b (Hib) one month after completion of the mixed schedule\n\nSecondary objectives\n\n* To describe the antibody response to all PR5I antigens one month after completion of the mixed schedule\n* To describe the antibody response to meningococcal serogroup C (MCC) conjugate vaccine one month after the second dose of MenC vaccine\n* To describe the safety profile after each dose of study vaccines administered","primaryOutcome":{"measure":"Percentage of Participants With an Anti-Hepatitis B Surface Antigen (HBsAg) Antibody Titer ≥10 mIU/mL","timeFrame":"Month 5 (one month after receiving Vaccination 3)","effectByArm":[{"arm":"PR5I (V1); Pediacel® (V2); PR5I (V3)","deltaMin":98.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"46 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28583305"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":385},"commonTop":["Irritability","Crying","Somnolence","Injection site pain","Decreased appetite"]}}